The COVID-19 pandemic is over, but the virus that caused it is still here, sending thousands of people to the hospital each week and spinning off new variants with depressing regularity. The viruss exceptional ability to change and evade immune defenses has led the World Health Organization (WHO) to recommend annual updates to COVID-19 vaccines.
But some scientists worry that the remarkable success of the first COVID-19 vaccines may work against updated versions, undermining the utility of an annual vaccination program. A similar problem plagues the annual flu vaccine campaign; immunity elicited by one years flu shots can interfere with immune responses in subsequent years, reducing the vaccines effectiveness.
A new study by researchers at Washington University School of Medicine in St. Louis helps to address this question. Unlike immunity to influenza virus, prior immunity to SARS-CoV-2, the virus that causes COVID-19, doesnt inhibit later vaccine responses. Rather, it promotes the development of broadly inhibitory antibodies, the researchers report.
The study, available online in Nature, shows that people who were repeatedly vaccinated for COVID-19 initially receiving shots aimed at the original variant, followed by boosters and updated vaccines targeting variants generated antibodies capable of neutralizing a wide range of SARS-CoV-2 variants and even some distantly related coronaviruses. The findings suggest that periodic re-vaccination for COVID-19, far from hindering the bodys ability to recognize and respond to new variants, may instead cause people to gradually build up a stock of broadly neutralizing antibodies that protect them from emerging SARS-CoV-2 variants and some other coronavirus species as well, even ones that have not yet emerged to infect humans.
The first vaccine an individual receives induces a strong primary immune response that shapes responses to subsequent infection and vaccination, an effect known as imprinting, said senior authorMichael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine. In principle, imprinting can be positive, negative or neutral. In this case, we see strong imprinting that is positive, because its coupled to the development of cross-reactive neutralizing antibodies with remarkable breadth of activity.
Imprinting is the natural result of how immunological memory works. A first vaccination triggers the development of memory immune cells. When people receive a second vaccination quite similar to the first, it reactivates memory cells elicited by the first vaccine. These memory cells dominate and shape the immune response to the subsequent vaccine.
Subscribe to Technology Networks daily newsletter, delivering breaking science news straight to your inbox every day.
To understand how imprinting influences the immune response to repeat COVID-19 vaccination, Diamond and colleagues including first author Chieh-Yu Liang, a graduate student, studied the antibodies from mice or people who had received a sequence of COVID-19 vaccines and boosters targeting first the original and then omicron variants. Some of the human participants also had been naturally infected with the virus that causes COVID-19.
The first question was the strength of the imprinting effect. The researchers measured how many of the participants neutralizing antibodies were specific for the original variant, the omicron variant or both. They found that very few people had developed any antibodies unique to omicron, a pattern indicative of strong imprinting by the initial vaccination. But they also found few antibodies unique to the original variant. The vast majority of neutralizing antibodies cross-reacted with both.
The next question was how far the cross-reactive effect extended. Cross-reactive antibodies, by definition, recognize a feature shared by two or more variants. Some features are shared only by similar variants, others by all SARS-CoV-2 variants or even all coronaviruses. To assess the breadth of the neutralizing antibodies, the researchers tested them against a panel of coronaviruses, including SARS-CoV-2 viruses from two omicron lineages; a coronavirus from pangolins; the SARS-1 virus that caused the 2002-03 SARS epidemic; and the Middle Eastern Respiratory Syndrome (MERS) virus. The antibodies neutralized all the viruses except MERS virus, which comes from a different branch of the coronavirus family tree than the others.
Further experiments revealed that this remarkable breadth was due to the combination of original and variant vaccines. People who received only the vaccines targeting the original SARS-CoV-2 variant developed some cross-reactive antibodies that neutralized the pangolin coronavirus and SARS-1 virus, but the levels were low. After boosting with an omicron vaccine, though, the cross-reactive neutralizing antibodies against the two coronavirus species increased.
Taken together, the findings suggest that regular re-vaccination with updated COVID-19 vaccines against variants might give people the tools to fight off not only the SARS-CoV-2 variants represented in the vaccines, but also other SARS-CoV-2 variants and related coronaviruses, possibly including ones that have not yet emerged.
At the start of the COVID-19 pandemic, the world population was immunologically nave, which is part of the reason the virus was able to spread so fast and do so much damage, said Diamond, also a professor of molecular microbiology and of pathology & immunology. We do not know for certain whether getting an updated COVID-19 vaccine every year would protect people against emerging coronaviruses, but its plausible. These data suggest that if these cross-reactive antibodies do not rapidly wane we would need to follow their levels over time to know for certain they may confer some or even substantial protection against a pandemic caused by a related coronavirus.
Reference:Liang CY, Raju S, Liu Z, et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature. 2024. doi: 10.1038/s41586-024-07539-1
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
Original post:
COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Associated Press - January 8th, 2024 [January 8th, 2024]
- TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration - Business Wire - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former Westside Pavilion into centers for research on immunology and quantum science - KABC-TV - January 8th, 2024 [January 8th, 2024]
- HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases - PR Newswire - January 8th, 2024 [January 8th, 2024]
- Beyond Cytotoxicity: The Importance of T Cell Memory - The Scientist - January 8th, 2024 [January 8th, 2024]
- IKAROS: Unlocking the secrets of the immune system's key player - News-Medical.Net - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Caledonian-Record - January 8th, 2024 [January 8th, 2024]
- Revolutionizing Vaccine Research: The Power of a New Algorithm - SciTechDaily - December 31st, 2023 [December 31st, 2023]
- Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people ... - Nature.com - December 22nd, 2023 [December 22nd, 2023]
- Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis - News-Medical.Net - December 22nd, 2023 [December 22nd, 2023]
- Physician and Patient (Un)Wellness in Allergy and Immunology During COVID-19 and Beyond: Lessons for the Future - Physician's Weekly - December 22nd, 2023 [December 22nd, 2023]
- Researchers Identify Why Some Cancers Do Not Respond to Immunotherapy - NYU Langone Health - December 22nd, 2023 [December 22nd, 2023]
- MU's Haval Shirwan recognized for achievements in immunology - Columbia Daily Tribune - December 22nd, 2023 [December 22nd, 2023]
- Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium - Weill Cornell Medicine Newsroom - December 14th, 2023 [December 14th, 2023]
- Annals of Allergy, Asthma and Immunology Examines Effects of Climate Change on Allergic Conditions - Newswise - December 14th, 2023 [December 14th, 2023]
- British Society for Immunology response to the NHS vaccination strategy - British Society for Immunology | - December 14th, 2023 [December 14th, 2023]
- NYU Langone Health in the NewsFriday, December 8, 2023 - NYU Langone Health - December 14th, 2023 [December 14th, 2023]
- Arturo Casadevall Named Distinguished Fellow by the American Association of Immunologists - Johns Hopkins Bloomberg School of Public Health - December 14th, 2023 [December 14th, 2023]
- ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scien - PharmiWeb.com - December 14th, 2023 [December 14th, 2023]
- Ishares Genomics Immunology And Healthcare Etf ($IDNA) Proactive Strategies - Stock Traders Daily - December 14th, 2023 [December 14th, 2023]
- Medical Breakthroughs Fueling Infection Prevention Market: Immunology and Modern Medicine Advancements to ... - PR Newswire - December 14th, 2023 [December 14th, 2023]
- Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided the detection of the immune ... - EurekAlert - December 14th, 2023 [December 14th, 2023]
- Testing Cancer Immunotherapies on Mice with Human Immune Systems - Mirage News - December 14th, 2023 [December 14th, 2023]
- Georgetown School of Medicine's Department of Immunology Hosts Talk About Therapeutic Vaccine for Autoimmune ... - Georgetown University The Hoya - December 6th, 2023 [December 6th, 2023]
- Long COVID Research Is a Bit of a Mess - Technology Networks - December 6th, 2023 [December 6th, 2023]
- Research Assistant/Research Associate in Immunology job with ... - Times Higher Education - May 13th, 2023 [May 13th, 2023]
- Pioneering learning resource helps academic win top teaching award - Swansea University - May 13th, 2023 [May 13th, 2023]
- 12 Months of Treatment with EPIT Superior to Placebo in ... - UNC Health and UNC School of Medicine - May 13th, 2023 [May 13th, 2023]
- Director of Discover Biology, Neuroscience & Immunology- full-time ... - Merck KGaA - May 13th, 2023 [May 13th, 2023]
- Absci, The Kennedy Institute for immunotherapies development - Pharmaceutical Technology - May 13th, 2023 [May 13th, 2023]
- Customizing T Cell-Based Immunotherapies in a 'SNAP' - UPMC - May 13th, 2023 [May 13th, 2023]
- Understanding Lupus: an interview with the Garvan Institute - News-Medical.Net - May 13th, 2023 [May 13th, 2023]
- Professor Laura Mackay wins LEO Foundation Award in Region ... - The Peter Doherty Institute for Infection and Immunity - May 13th, 2023 [May 13th, 2023]
- Trinity's Prof Ed Lavelle recognised by ISI for vaccine research - SiliconRepublic.com - May 13th, 2023 [May 13th, 2023]
- Allison Institute announces appointment of inaugural members - EurekAlert - May 13th, 2023 [May 13th, 2023]
- Study sheds light on how the immune system protects the body - EurekAlert - May 13th, 2023 [May 13th, 2023]
- Werewolf Therapeutics Reports First Quarter 2023 Financial Results ... - BioSpace - May 13th, 2023 [May 13th, 2023]
- PeaceHealth cuts Bellingham jobs, announces clinic closure and reduces some services - Yahoo News - May 13th, 2023 [May 13th, 2023]
- Help! My skin is itchy - Parkview Health - May 13th, 2023 [May 13th, 2023]
- Takeda reports 12.8% rise in FY2022 revenue - Pharmaceutical Technology - May 13th, 2023 [May 13th, 2023]
- Welcoming a new column: Vasso's corner - The immune system - Neos Kosmos - May 13th, 2023 [May 13th, 2023]
- UC statement on Gov. Newsom's 2023-24 revised budget proposal - University of California - May 13th, 2023 [May 13th, 2023]
- Jasper Therapeutics (JSPR) Appoints Stephen J. Galli to its Board - StreetInsider.com - May 13th, 2023 [May 13th, 2023]